Abstract
Different approaches of LRCT using sealed and unsealed radionuclides are reexamined and contrasted to allow optimal choice to treat human cancers. With the production of devices of smaller particulate sizes and of soluble radiopharmaceuticals of more potency and longer half-life, the distinction of sealed versus unsealed radiopharmaceuticals differs only in the choice of compliance pathways and becomes less important. There are many choices of radiopharmaceuticals for LRCT such as sealed versus unsealed radiopharmaceuticals, those with versus those without tumor affinity, and particulate versus soluble forms. These choices will allow treating human cancer with less toxic and more efficacious applications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J. 2017;6(4):187–96.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27(7):766–77.
Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2005;32(4):458–69.
Delouya G, Bahary P, Carrier JF, Larouche RX, Hervieux Y, Beliveau-Nadeau D, et al. Refining prostate seed brachytherapy: comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy. Brachytherapy. 2015;14(3):329–33.
Stubbs JB, Strickland AD, Frank RK, Simon J, McMillan K, Williams JA. Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors. Cancer Biother Radiopharm. 2000;15(6):645–56.
Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, et al. Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection. J Cancer Res Ther. 2010;6(1):65–74.
Arnold CA, Pezhouh MK, Lam-Himlin D, Pittman ME, VandenBussche C, Voltaggio L. 90Y-TheraSpheres: the new look of Yttrium-90. Am J Surg Pathol. 2019;43(5):688–94.
Aranda E, Aparicio J, Bilbao JI, Garcia-Alfonso P, Maurel J, Rodriguez J, et al. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. Future Oncol. 2017;13(23):2065–82.
Javed S, Bhutani MS. Endoscopic ultrasound-guided radiation therapy in pancreatic cancer. Minerva Gastroenterol Dietol. 2013;59(4):377–86.
Gobitti C, Borsatti E, Arcicasa M, Roncadin M, Franchin G, Minatel E, et al. Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori. 2011;97(5):614–9.
de Campos TP, Nogueira LB, Trindade B, Cuperschmid EM. Dosimetric intercomparison of permanent Ho-166 seed’s implants and HDR Ir-192 brachytherapy in breast cancer. Rep Pract Oncol Radiother. 2016;21(3):240–9.
Marinelli LD, Trunnell JB, et al. Factors involved in the experimental therapy of metastatic thyroid cancer with I131; a preliminary report. Radiology. 1948;51(4):553–7.
Soley MH, Miller ER, Foreman N. Graves’ disease; treatment with radioiodine (I131). Miss Valley Med J. 1949;71(4):131–4.
Marinelli LD, Hill RF. Radiation dosimetry in the treatment of functional thyroid carcinoma with I131. Radiology. 1950;55(4):494–501.
Sparks RB, Crowe EA, Wong FC, Toohey RE, Siegel JA. Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity. J Nucl Med. 2002;43(8):1110–4.
Gholami YH, Wilson N, James D, Kuncic Z. Toward personalized dosimetry with (32)P microparticle therapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):1029–38.
Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, Singh BS, Wong FCL, Erwin WD, et al. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019;4(5):223–5.
Reardon S. Whole-body PET scanner produces 3D images in seconds. Nature. 2019;570(7761):285–6.
Wong FC, Boja J, Ho B, Kuhar MJ, Wong DF. Affinity labeling of membrane receptors using tissue-penetrating radiations. Biomed Res Int. 2013;2013:503095.
Bellia SR, Feliciani G, Duca MD, Monti M, Turri V, Sarnelli A, et al. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. J Contemp Brachytherapy. 2019;11(5):449–57.
Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280(1):249–79.
Bonvalot S, Rutkowski PL, Thariat J, Carrere S, Ducassou A, Sunyach MP, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148–59.
Pottier A, Borghi E, Levy L. New use of metals as nanosized radioenhancers. Anticancer Res. 2014;34(1):443–53.
Deagostino A, Protti N, Alberti D, Boggio P, Bortolussi S, Altieri S, et al. Insights into the use of gadolinium and gadolinium/boron-based agents in imaging-guided neutron capture therapy applications. Future Med Chem. 2016;8(8):899–917.
Yeh CN, Chang CW, Chung YH, Tien SW, Chen YR, Chen TW, et al. Synthesis and characterization of boron fenbufen and its F-18 labeled homolog for boron neutron capture therapy of COX-2 overexpressed cholangiocarcinoma. Eur J Pharm Sci. 2017;107:217–29.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wong, F.C.L. (2021). Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed and Unsealed Radionuclides. In: Wong, F.C. (eds) Locoregional Radionuclide Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-56267-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-56267-0_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56266-3
Online ISBN: 978-3-030-56267-0
eBook Packages: MedicineMedicine (R0)